Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Next15 says trading robust, approves new share purchases

(Sharecast News) - Next Fifteen Group told investors that results for the financial year were seen coming in as expected.

In a pre-close trading update, the growth consultancy also said that sales were seen rising by 3% over the 12 months ending on 31 January and by 1% during the back half of the year.

Trading across all segments of the business were described as "robust" and its deepening relationship with a number of existing clients gave management confidence that growth was set to accelerate over the next financial year.

The company's net debt was expected to be "modest" by year end, giving management flexibility to execute strategic and bolt-on acquisitions as they arose.

Next 15 also announced that it had instructed Deutsche Bank to proceed with an additional £10m-worth of share repurchases under its existing authorisation.

As of 1126 GMT, shares of Next 15 Group were trading up by 4.07% to 843.0p.

Share this article

Related Sharecast Articles

Biome Technologies shares sink as Q1 sales drop 44%
(Sharecast News) - Shares in AIM-listed Biome Technologies plummeted by almost a third on Monday after the bioplastics and radio frequency technology business reported a poor start to the year with first-quarter sales dropping by 44%.
Entain reprices two term loans, revises interest cost outlook
(Sharecast News) - Betting and gambling giant Entain announced the successful repricing of two of its existing 'Term Loan B' loans on Monday, along with the pricing and allocation of fungible add-ons, in a bid to optimise its financial position.
Oxford Biomedica confident as it moves away from vaccine era
(Sharecast News) - Cell and gene therapy contract development and manufacturing organisation (CDMO) Oxford Biomedica reported stability in its core business on Monday, with a small increase in full-year core revenue for 2023, despite a 36% decrease in total revenue to £89.5m.
N Brown chairman Ron McMillan to retire
(Sharecast News) - N Brown said on Monday that chairman Ron McMillan will be retiring and stepping down from the board with effect from 30 April for personal reasons.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.